Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Neuropharmacology ; 126: 38-47, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-28842344

RESUMEN

Autism spectrum disorder (ASD) is associated with two core symptoms (social communication deficits and stereotyped repetitive behaviors) in addition to a number of comorbidities. There are no FDA-approved drugs for the core symptoms and the changes that underlie these behaviors are not fully understood. One hypothesis is an imbalance of the excitation (E)/inhibition (I) ratio with excessive E and diminished I occurring in specific neuronal circuits. Data suggests that both gamma-aminobutyric acidA (GABAA) and α7 nicotinic acetylcholine receptors (nAChRs) significantly impact E/I. BTBR T+tf/J (BTBR) mice are a model that display an autism-like phenotype with impaired social interaction and stereotyped behavior. A ß2/3-subunit containing GABAA receptor (GABAAR) subtype selective positive allosteric modulator (PAM), 2-261, and an α7 nAChR subtype selective PAM, AVL-3288, were tested in social approach and repetitive self-grooming paradigms. 2-261 was active in the social approach but not the self-grooming paradigm, whereas AVL-3288 was active in both. Neither compound impaired locomotor activity. Modulating α7 nAChRs alone may be sufficient to correct these behavioral and cognitive deficits. GABAergic and nicotinic compounds are already in various stages of clinical testing for treatment of the core symptoms and comorbidities associated with ASD. Our findings and those of others suggest that compounds that have selective activities at GABAAR subtypes and the α7 nAChR may address not only the core symptoms, but many of the associated comorbidities as well and warrant further investigation in other models of ASD.


Asunto(s)
Trastorno del Espectro Autista/fisiopatología , Conducta Animal/efectos de los fármacos , Receptores de GABA-A/fisiología , Receptor Nicotínico de Acetilcolina alfa 7/fisiología , Regulación Alostérica , Anilidas/administración & dosificación , Animales , Trastorno del Espectro Autista/prevención & control , Modelos Animales de Enfermedad , Aseo Animal/efectos de los fármacos , Humanos , Isoxazoles/administración & dosificación , Masculino , Ratones Endogámicos C57BL , Ratones Transgénicos , Actividad Motora/efectos de los fármacos , Conducta Social
2.
J Psychopharmacol ; 31(4): 434-441, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-28196430

RESUMEN

Type I positive allosteric modulators (PAMs) of the alpha7-nicotinic receptor enhance its cholinergic activation while preserving the spatiotemporal features of synaptic transmission and the receptor's characteristic rapid desensitization kinetics. Alpha7-nicotinic receptor agonists have shown promise for improving cognition in schizophrenia, but longer-term trials have been disappointing. Therefore, the type I PAM AVL-3288 was evaluated for safety and preliminary evidence of neurocognitive effect in healthy human subjects. Single-dose oral administration in ascending doses was conducted in a double-blind, placebo-controlled Phase I trial in non-smokers. The trial found indication of positive but non-significant effects on neurocognition at 10 and 30 mg, two doses that produced overlapping peak levels. There was also some evidence for effects on inhibition of the P50 auditory evoked potential to repeated stimuli, a biomarker that responds to alpha7-nicotinic receptor activation. The pharmacokinetic characteristics were consistent between subjects, and there were no safety concerns. The effects and safety profile were also assessed at 3 mg in a cohort of smokers, in whom concurrent nicotine administration did not alter either effects or safety. The trial demonstrates that a type I PAM can be safely administered to humans and that it has potential positive neurocognitive effects in central nervous system (CNS) disorders.


Asunto(s)
Regulación Alostérica/efectos de los fármacos , Anilidas/efectos adversos , Anilidas/uso terapéutico , Isoxazoles/efectos adversos , Isoxazoles/uso terapéutico , Trastornos Neurocognitivos/tratamiento farmacológico , Receptor Nicotínico de Acetilcolina alfa 7/metabolismo , Adulto , Anilidas/farmacocinética , Biomarcadores/metabolismo , Cognición/efectos de los fármacos , Método Doble Ciego , Femenino , Humanos , Isoxazoles/farmacocinética , Masculino , Trastornos Neurocognitivos/metabolismo , Nicotina/administración & dosificación , Agonistas Nicotínicos/efectos adversos , Agonistas Nicotínicos/farmacocinética , Agonistas Nicotínicos/uso terapéutico , Receptores Nicotínicos/metabolismo , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/metabolismo , Transmisión Sináptica/efectos de los fármacos , Adulto Joven
3.
Psychopharmacology (Berl) ; 231(17): 3517-24, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24682501

RESUMEN

RATIONALE: In order to improve upon the pharmacological properties of the neuroactive steroid ganaxolone, it was used as the starting point in the design of novel neurosteroids that replace the 17ß-acetyl side chain with an isoxazole bioisostere. OBJECTIVES: UCI-50027 (3-[3α-hydroxy-3ß-methyl-5α-androstan-17ß-yl]-5-(hydroxymethyl)isoxazole) was designed as an orally active neuroactive steroid specifically targeted at the gamma-aminobutyric acid(A) receptor (GABAAR). METHODS: UCI-50027 was tested in vitro in Xenopus oocytes expressing human GABAARs and in vivo as an anticonvulsant, for ataxic effects and for anxiolytic activity. RESULTS: In vitro, UCI-50027 dose-dependently enhanced the activity of GABA at human α1ß2γ2L, α2ß1γ2L, and α4ß3δ GABAARs. Consistent with its action as a positive allosteric modulator (PAM), it had no direct activity in the absence of GABA. UCI-50027 protected against acute pentylenetetrazol (PTZ)-induced convulsions with an ED50 of 6 mg/kg p.o. In the rotarod (RR) paradigm in mice, the AD50 (the ataxic dose where half of the animals fail the RR test) was found to be 38 mg/kg p.o., giving a therapeutic index (TI = RR AD50/PTZ ED50)∼6 versus 2.8 for ganaxolone. In the mouse-elevated plus maze (EPM) model for anxiety, UCI-50027 showed a minimum effective dose (MED) ≤0.3 mg/kg p.o. Thus, the TI (TI = RR AD50/EPM MED) for the compound as an anxiolytic is ≥127 versus 3.3 for ganaxolone. CONCLUSIONS: UCI-50027 is an orally active neuroactive steroid with pharmacological activity consistent with a GABAAR PAM that has an improved separation between anticonvulsant/anxiolytic and rotarod effects, potent activity as an anticonvulsant and anxiolytic when compared to ganaxolone.


Asunto(s)
Androstanos/farmacología , Neurotransmisores/farmacología , Animales , Ansiolíticos/farmacología , Anticonvulsivantes/farmacología , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Neurotransmisores/farmacocinética , Técnicas de Placa-Clamp , Pentilenotetrazol/antagonistas & inhibidores , Equilibrio Postural/efectos de los fármacos , Pregnanolona/análogos & derivados , Pregnanolona/farmacocinética , Pregnanolona/farmacología , Ratas , Ratas Sprague-Dawley , Receptores de GABA-A/efectos de los fármacos , Xenopus
4.
J Psychopharmacol ; 28(5): 472-8, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24108410

RESUMEN

GABAergic anxiolytics have well-documented centrally mediated side effects including sedation, potentiation of ethanol, tolerance, abuse liability and memory impairment. Most research directed towards identifying an anxioselective GABAergic therapeutic has been based upon the theory that these side effects could be mitigated by avoiding α1/5-subunit GABAA receptors while specifically targeting those with the α2/3-subunit. Unfortunately, there are prominent exceptions to this theory and it has yet to be translated into clinical success. We previously demonstrated that ß2/3-subunit-selective GABAA receptor-positive allosteric modulators act as anxiolytics with reduced sedation and ethanol potentiation regardless of their activity at α1-subunit GABAA receptors. The prototypical ß2/3-subunit-selective positive allosteric modulator, 2-261, is further characterized here for additional side effects commonly associated with central GABAA receptor activation. In mice, 10 times the anxiolytic dose (10 mg/kg) of 2-261 does not induce behavioral tolerance in the elevated plus maze following a 2 week subchronic treatment. In rats, an anxiolytic dose (10 mg/kg) of 2-261 is inactive in conditioned place preference, suggesting a reduced abuse liability. In rats, 10 times the anxiolytic dose (100 mg/kg) of 2-261 does not have a significant amnestic effect in the radial arm maze, suggesting a greater therapeutic index for memory impairment. These results suggest that ß2/3-subunit subtype-selective GABAA receptor-positive allosteric modulators not only have reduced sedative liability, but also a reduction in other central side effects commonly associated with broader GABAA receptor activation. ß2/3-subunit-selective compounds may represent a novel design template for anxiolytics with benzodiazepine-like efficacy and mitigated side effects.


Asunto(s)
Regulación Alostérica/efectos de los fármacos , Ansiolíticos/administración & dosificación , Agonistas de Receptores de GABA-A/administración & dosificación , Receptores de GABA-A/metabolismo , Animales , Etanol/metabolismo , Hipnóticos y Sedantes/administración & dosificación , Ratones , Ratas , Ratas Sprague-Dawley
5.
J Med Chem ; 56(21): 8352-65, 2013 Nov 14.
Artículo en Inglés | MEDLINE | ID: mdl-24098954

RESUMEN

A series of novel arylpyrid-3-ylmethanones (7a-aa) were designed as modulators of α7 nicotinic acetylcholine receptors (nAChRs). The methanones were found to be type I positive allosteric modulators (PAMs) of human α7 nAChRs expressed in Xenopus ooctyes. Structure-activity relationship (SAR) studies resulted in the identification of compound 7v as a potent and efficacious type I PAM with maximum modulation of a nicotine EC5 response of 1200% and EC50 = 0.18 µM. Compound 7z was active in reversing the effect of scopolamine in the novel object recognition (NOR) paradigm with a minimum effective ip dose of 1.0 mg/kg (2.7 µmol/kg). This effect was blocked by the selective α7 nAChR antagonist methyllycaconitine (MLA). These compounds are potent type I positive allosteric modulators of α7 nAChRs that may have therapeutic value in restoring impaired sensory gating and cognitive deficits in schizophrenia and Alzheimer's disease.


Asunto(s)
Diseño de Fármacos , Piridinas/farmacología , Receptor Nicotínico de Acetilcolina alfa 7/antagonistas & inhibidores , Regulación Alostérica/efectos de los fármacos , Animales , Sitios de Unión/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Humanos , Ratones , Estructura Molecular , Oocitos/química , Oocitos/efectos de los fármacos , Oocitos/metabolismo , Piridinas/síntesis química , Piridinas/química , Relación Estructura-Actividad , Xenopus , Receptor Nicotínico de Acetilcolina alfa 7/biosíntesis
6.
J Pharmacol Exp Ther ; 336(3): 908-15, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21159751

RESUMEN

α5 Subunit-containing GABA(A) receptors (GABA(A)Rs) and α7 neuronal nicotinic-acetylcholine receptors (nAChRs) are members of the Cys-loop family of ligand-gated ion channels (LGICs) that mediate cognitive and attentional processes in the hippocampus. α5 GABA(A)Rs alter network activity by tonic inhibition of CA1/CA3 pyramidal cells of the hippocampus. Postsynaptic α7 nAChRs in the hippocampus regulate inhibitory GABAergic interneuron activity required for synchronization of pyramidal neurons in the CA1, whereas presynaptic α7 nAChRs regulate glutamate release. Can simultaneous allosteric modulation of these LGICs produce synergistic effects on cognition? We show that combined transient application of two allosteric modulators that individually 1) inhibit α5 GABA(A)Rs and 2) enhance α7 nAChRs causes long-term potentiation (LTP) of mossy fiber stimulation-induced excitatory postsynaptic currents (EPSC) from CA1 pyramidal neurons of rat hippocampal slices. The LTP effect evoked by two compounds is replicated by 3-(2,5-difluorophenyl)-6-(N-ethylindol-5-yl)-1,2,4-triazolo[4,3-b]pyridazine (522-054), a compound we designed to simultaneously inhibit α5 GABA(A)Rs and enhance α7 nAChRs. Selective antagonists for either receptor block sustained EPSC potentiation produced by 522-054. In vivo, 522-054 enhances performance in the radial arm maze and facilitates attentional states in the five-choice serial reaction time trial with similar receptor antagonist sensitivity. These observations may translate into therapeutic utility of dual action compounds in diseases of hippocampal-based cognitive impairment.


Asunto(s)
Cognición/fisiología , Hipocampo/fisiología , Canales Iónicos Activados por Ligandos/fisiología , Potenciación a Largo Plazo/fisiología , Regulación Alostérica/efectos de los fármacos , Regulación Alostérica/fisiología , Animales , Cognición/efectos de los fármacos , Femenino , Hipocampo/efectos de los fármacos , Indoles/química , Indoles/farmacología , Potenciación a Largo Plazo/efectos de los fármacos , Masculino , Ratas , Ratas Sprague-Dawley , Ratas Wistar , Receptores de GABA-A/fisiología , Receptores Nicotínicos/fisiología , Xenopus laevis , Receptor Nicotínico de Acetilcolina alfa 7
7.
J Pharmacol Exp Ther ; 332(3): 1040-53, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19940102

RESUMEN

GABA(A) receptor (R) positive allosteric modulators that selectively modulate GABA(A)Rs containing beta(2)- and/or beta(3)- over beta(1)-subunits have been reported across diverse chemotypes. Examples include loreclezole, mefenamic acid, tracazolate, and etifoxine. In general,"beta(2/3)-selective" GABA(A)R positive allosteric modulators are nonbenzodiazepines (nonBZs), do not show alpha-subunit isoform selectivity, yet have anxiolytic efficacy with reduced ataxic/sedative effects in animal models and humans. Here, we report on an enantiomeric pair of nonBZ GABA(A)R positive allosteric modulators that demonstrate differential beta-subunit isoform selectivity. We have tested this enantiomeric pair along with a series of other beta(2/3)-subunit selective, alpha-subunit isoform-selective, BZ and nonBZ GABA(A) positive allosteric modulators using electrophysiological, pharmacokinetic, and behavioral assays to test the hypothesis that ataxia may be correlated with the extent of modulation at beta(1)-subunit-containing GABA(A)Rs. Our findings provide an alternative strategy for designing anxioselective allosteric modulators of the GABA(A)R with BZ-like anxiolytic efficacy by reducing or eliminating activity at beta(1)-subunit-containing GABA(A)Rs.


Asunto(s)
Ansiolíticos/farmacología , Ataxia/prevención & control , Moduladores del GABA/farmacología , Receptores de GABA-A/fisiología , Regulación Alostérica , Amidas/química , Amidas/farmacocinética , Amidas/farmacología , Animales , Ansiolíticos/química , Ansiolíticos/farmacocinética , Ataxia/fisiopatología , Ataxia/psicología , Conducta Animal/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Moduladores del GABA/química , Moduladores del GABA/farmacocinética , Humanos , Masculino , Ratones , Oocitos/efectos de los fármacos , Oocitos/fisiología , Técnicas de Placa-Clamp , Isoformas de Proteínas/fisiología , Ratas , Ratas Sprague-Dawley , Estereoisomerismo , Relación Estructura-Actividad , Xenopus laevis
8.
J Pharmacol Exp Ther ; 323(3): 907-15, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17873105

RESUMEN

Drugs that antagonize nicotinic acetylcholine receptors (nAChRs) can be used to inhibit nicotine-induced behavior in both humans and animals. The aim of our experiments is to establish a proof-of-principle that antagonism of nAChRs by negative allosteric modulation can alter behavior in a relevant animal model of addiction, nicotine self-administration. We have identified a novel, negative allosteric modulator of nAChRs, UCI-30002 [N-(1,2,3,4-tetrahydro-1-naphthyl)-4-nitroaniline], with selectivity for the major neuronal nAChR subtypes over muscle-type nAChRs. After systemic administration, UCI-30002 significantly reduces nicotine self-administration in rats on both fixed ratio and progressive ratio schedules of reinforcement. The minimum effective dose that significantly alters nicotine self-administration corresponds to brain concentrations of UCI-30002 that produce at least 30% inhibition of the major neuronal nAChR subtypes measured in vitro. UCI-30002 has no effect on responding for food reinforcement in rats on either type of schedule, indicating that there is no effect on general responding or natural reward. UCI-30002 represents validation of the concept that negative allosteric modulators may have significant benefits as a strategy for treating nicotine addiction and encourages the development of subtype-selective modulators.


Asunto(s)
Compuestos de Anilina/uso terapéutico , Naftalenos/uso terapéutico , Nicotina/administración & dosificación , Antagonistas Nicotínicos/uso terapéutico , Receptores Nicotínicos/metabolismo , Tabaquismo , Sitio Alostérico , Compuestos de Anilina/administración & dosificación , Compuestos de Anilina/efectos adversos , Animales , Membrana Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Electrofisiología , Conducta Alimentaria/efectos de los fármacos , Conducta Alimentaria/etnología , Ligandos , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Naftalenos/administración & dosificación , Naftalenos/efectos adversos , Nicotina/efectos adversos , Antagonistas Nicotínicos/administración & dosificación , Antagonistas Nicotínicos/efectos adversos , Antagonistas Nicotínicos/farmacocinética , Oocitos/efectos de los fármacos , Oocitos/fisiología , Técnicas de Placa-Clamp , Unión Proteica , Ratas , Ratas Sprague-Dawley , Convulsiones/inducido químicamente , Convulsiones/prevención & control , Autoadministración , Tabaquismo/tratamiento farmacológico , Tabaquismo/metabolismo , Xenopus laevis
9.
J Med Chem ; 50(14): 3369-79, 2007 Jul 12.
Artículo en Inglés | MEDLINE | ID: mdl-17571865

RESUMEN

A series of enaminone esters and amides have been developed as potent allosteric modulators of gamma-aminobutyric acidA (GABAA) receptors. The compounds bind to a novel modulatory site that is independent of the benzodiazepine (BZ), isosteric GABA, and neuroactive steroid binding sites. Structure-activity relationship (SAR) studies resulted in the synthesis of the c-Bu amide 16h with an in vitro potency of 7 nM based on inhibition of [35S]TBPS binding. The activity of the enaminones as positive allosteric modulators was confirmed with electrophysiological measurements in oocytes expressing alpha1beta2gamma2L GABAA receptors. The i-Pr, s-Bu, c-Pr, and c-Bu amides (16e-h) were orally active in mice with profound central nervous system depressant effects. The i-Pr amide 16e was an orally active anxiolytic in the mouse light-dark paradigm.


Asunto(s)
Amidas/farmacología , Receptores de GABA-A/efectos de los fármacos , Administración Oral , Animales , Espectroscopía de Resonancia Magnética , Masculino , Ratones , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad
10.
Proc Natl Acad Sci U S A ; 104(19): 8059-64, 2007 May 08.
Artículo en Inglés | MEDLINE | ID: mdl-17470817

RESUMEN

Activation of brain alpha7 nicotinic acetylcholine receptors (alpha7 nAChRs) has broad therapeutic potential in CNS diseases related to cognitive dysfunction, including Alzheimer's disease and schizophrenia. In contrast to direct agonist activation, positive allosteric modulation of alpha7 nAChRs would deliver the clinically validated benefits of allosterism to these indications. We have generated a selective alpha7 nAChR-positive allosteric modulator (PAM) from a library of GABAA receptor PAMs. Compound 6 (N-(4-chlorophenyl)-alpha-[[(4-chloro-phenyl)amino]methylene]-3-methyl-5-isoxazoleacet-amide) evokes robust positive modulation of agonist-induced currents at alpha7 nAChRs, while preserving the rapid native characteristics of desensitization, and has little to no efficacy at other ligand-gated ion channels. In rodent models, it corrects sensory-gating deficits and improves working memory, effects consistent with cognitive enhancement. Compound 6 represents a chemotype for allosteric activation of alpha7 nAChRs, with therapeutic potential in CNS diseases with cognitive dysfunction.


Asunto(s)
Moduladores del GABA/farmacología , Nootrópicos/farmacología , Receptores de GABA-A/efectos de los fármacos , Receptores Nicotínicos/efectos de los fármacos , Animales , Encéfalo/metabolismo , Supervivencia Celular/efectos de los fármacos , Cognición/efectos de los fármacos , Maleato de Dizocilpina/farmacología , Humanos , Masculino , Ratones , Ratones Endogámicos DBA , Ratas , Ratas Sprague-Dawley , Xenopus laevis , Receptor Nicotínico de Acetilcolina alfa 7
11.
J Drug Target ; 14(3): 127-36, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16753826

RESUMEN

The endogenous opioid peptide leu-enkephalin (ENK) was chemically modified by a method known as reversible aqueous lipidization (REAL) with a novel amine-reacting lipophilic dimethylmaleic anhydride analog, 3,4-bis(decylthiomethyl)-2,5-furandione. The binding affinity of the product, REAL-ENK, to opioid receptors was greatly reduced. This prodrug was stable in neutral and basic phosphate buffers but underwent rapid hydrolysis under acidic conditions in the presence of 50% acetonitrile. It also showed increased stability toward enzymatic degradations in various tissue preparations. The half-lives of REAL-ENK in mouse small intestinal mucosal homogenate and liver homogenate were 12 and 80 min, representing a 12- and 32-fold increase over those of ENK itself. In contrast to ENK (t(1/2) 6.7 min), REAL-ENK was stable in mouse plasma. More importantly, REAL-ENK produced significant and sustained antinociception mediated by peripheral opioid receptors in a rodent inflammatory pain model. Pharmacokinetic studies employing a radioimmunoassay (RIA) demonstrated that significantly higher and sustained plasma peptide levels were detected up to 24 h following the oral administration of REAL-ENK in normal mice. The peak concentration and area under the curve of oral REAL-ENK were 4.4 and 21 times higher than that of oral ENK. Our results indicate that like its disulfide-based counterpart, amine-based REAL may be an enabling technology which can be applied to enhance metabolic stability, increase oral absorption, and preserve and possibly prolong the pharmacological activity of peptide drugs.


Asunto(s)
Encefalina Leucina/administración & dosificación , Lípidos/química , Administración Oral , Animales , Células CACO-2 , Encefalina Leucina/química , Encefalina Leucina/farmacocinética , Semivida , Humanos , Mucosa Intestinal/metabolismo , Intestino Delgado/metabolismo , Hígado/metabolismo , Ratones , Radioinmunoensayo , Distribución Tisular
12.
Nat Med ; 10(1): 31-2, 2004 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-14647497

RESUMEN

Patients taking fluoroquinolone antibiotics such as norfloxacin exhibit a low incidence of convulsions and anxiety. These side effects probably result from antagonism of the neurotransmitter gamma-aminobutyric acid (GABA) at the brain GABA(A) receptor complex (GRC). Modification of norfloxacin yields molecules such as compound 4 that potentiate GABA action with alpha(2) subunit selectivity. Compound 4 is anxiolytic but does not cause sedation, and may represent a new class of ligands that have anxiolytic activity without sedative liability.


Asunto(s)
Ansiolíticos/farmacología , Antiinfecciosos/farmacología , Fluoroquinolonas/farmacología , Ansiolíticos/química , Ansiolíticos/metabolismo , Antiinfecciosos/química , Antiinfecciosos/metabolismo , Fluoroquinolonas/química , Fluoroquinolonas/metabolismo , Humanos , Unión Proteica , Receptores de GABA-A/metabolismo , Proteínas Recombinantes/metabolismo , Ácido gamma-Aminobutírico/metabolismo
13.
Br J Pharmacol ; 140(2): 402-12, 2003 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12970077

RESUMEN

1. Caspases play a critical role in apoptosis, and are considered to be key targets for the design of cytoprotective drugs. As part of our antiapoptotic drug-discovery effort, we have synthesized and characterized Z-VD-fmk, MX1013, as a potent, irreversible dipeptide caspase inhibitor. 2. MX1013 inhibits caspases 1, 3, 6, 7, 8, and 9, with IC50 values ranging from 5 to 20 nm. MX1013 is selective for caspases, and is a poor inhibitor of noncaspase proteases, such as cathepsin B, calpain I, or Factor Xa (IC50 values >10 microm). 3. In several cell culture models of apoptosis, including caspase 3 processing, PARP cleavage, and DNA fragmentation, MX1013 is more active than tetrapeptide- and tripeptide-based caspase inhibitors, and blocked apoptosis at concentrations as low as 0.5 microm. 4. MX1013 is more aqueous soluble than tripeptide-based caspase inhibitors such as Z-VAD-fmk. 5. At a dose of 1 mg kg-1 i.v., MX1013 prevented liver damage and the lethality caused by Fas death receptor activation in the anti-Fas mouse-liver apoptosis model, a widely used model of liver failure. 6. At a dose of 20 mg kg-1 (i.v. bolus) followed by i.v. infusion for 6 or 12 h, MX1013 reduced cortical damage by approximately 50% in a model of brain ischemia/reperfusion injury. 7. At a dose of 20 mg kg-1 (i.v. bolus) followed by i.v. infusion for 12 h, MX1013 reduced heart damage by approximately 50% in a model of acute myocardial infarction. 8. Based on these studies, we conclude that MX1013, a dipeptide pan-caspase inhibitor, has a good combination of in vitro and in vivo properties. It has the ability to protect cells from a variety of apoptotic insults, and is systemically active in three animal models of apoptosis, including brain ischemia.


Asunto(s)
Clorometilcetonas de Aminoácidos/farmacología , Apoptosis/efectos de los fármacos , Inhibidores de Cisteína Proteinasa/farmacología , Clorometilcetonas de Aminoácidos/síntesis química , Animales , Isquemia Encefálica/patología , Isquemia Encefálica/prevención & control , Caspasa 1/metabolismo , Caspasa 3 , Inhibidores de Caspasas , Caspasas/metabolismo , Cicloheximida/farmacología , Fragmentación del ADN/efectos de los fármacos , Dipéptidos/síntesis química , Dipéptidos/farmacología , Relación Dosis-Respuesta a Droga , Doxorrubicina/farmacología , Femenino , Células HeLa , Humanos , Células Jurkat , Hígado/efectos de los fármacos , Hígado/patología , Masculino , Ratones , Infarto del Miocardio/patología , Infarto del Miocardio/prevención & control , Poli(ADP-Ribosa) Polimerasas/metabolismo , Ratas , Ratas Endogámicas F344 , Factor de Necrosis Tumoral alfa/farmacología
14.
Bioorg Med Chem ; 11(8): 1769-80, 2003 Apr 17.
Artículo en Inglés | MEDLINE | ID: mdl-12659763

RESUMEN

A series of novel di- and trisubstituted 1,4-dihydroquinoxaline-2,3-diones (QXs) related to licostinel (Acea 1021) was synthesized and evaluated as antagonists for the glycine site of the N-methyl-D-asparate (NMDA) receptor. The in vitro potency of these antagonists was determined by displacement of the glycine site radioligand [(3)H]-5,7-dichlorokynurenic acid ([(3)H]DCKA) in rat brain cortical membranes. Structure-activity relationship studies indicate that a cyano group is a good replacement for the nitro group in the 5-position of licostinel while 5-carboxy, 5-ester, 5-ketone and 5-amide derivatives showed reduced potency. 5,6-Cyclized analogues of licostinel also showed significantly reduced potency. Among the trisubstituted QXs investigated, 5-cyano-6,7-dichloro QX and 5-cyano-7-chloro-6-methyl QX are the most potent with IC(50) values of 32 nM and 26 nM, respectively.


Asunto(s)
Glicina/metabolismo , Ácido Quinurénico/análogos & derivados , Quinoxalinas/química , Quinoxalinas/síntesis química , Quinoxalinas/farmacología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Animales , Sitios de Unión , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Corteza Cerebral/metabolismo , Glicina/antagonistas & inhibidores , Concentración 50 Inhibidora , Ácido Quinurénico/metabolismo , Ensayo de Unión Radioligante , Ratas , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA